Preview

User

Not a user? Register with this site Forgot your password?

Patient-Oriented Medicine and Pharmacy

Advanced search

Editorial Policies

Aim and Scope

The concept of patient-oriented in medicine and pharmacy represents a significant shift in the approach to providing medical care, where the key element is the patient with his/her individual needs, preferences and values. This approach emphasizes the importance of the patient's active participation in making decisions about his/her treatment, which corresponds to the slogan: "nothing that concerns me is done without me".

Key aspects of patient-oriented:

1. Personalization of treatment:

Use of personalized and precision medicine technologies, including genomic, epigenomic and metabolomic biomarkers. Development of algorithms for personalization of pharmacotherapy that take into account individual patient characteristics, such as genetic, ethnic and metabolic factors. Implementation of computerized clinical decision support systems that help physicians choose the optimal treatment for each patient.

2. Crisis of evidence-based medicine methodology:

Limitations of traditional clinical trials, which often evaluate the effectiveness of treatment on "average" patients, which does not always reflect real-worl clinical practice. The need to conduct research on real-world data (RWD) and real-world evidence (RWE) that take into account individual patient characteristics and their response to treatment.

3. The role of the patient in decision making:

Active patient participation in the choice of treatment methods, including the use of drugs. Taking into account the patient's preferences, values, and economic capabilities when developing a treatment plan.

4. Patient safety:

Studying tools to ensure safety in the use of drugs, including over-the-counter drugs. Development of pharmaceutical counseling and responsible self-medication.

5. Information technology:

Using digital and mobile technologies to bridge the gap between clinical research and real-world clinical practice. Development of the "mHealth" and "mResearch" areas, which allow collecting data on patients in real time and adapting treatment to their needs.

 

Section Policies

FROM EDITOR-IN-CHIEF
Checked Open Submissions Checked Indexed Checked Peer Reviewed
FROM PUBLISHER
Checked Open Submissions Checked Indexed Checked Peer Reviewed
LEADING ARTICLE
Checked Open Submissions Checked Indexed Checked Peer Reviewed
ACTUAL REVIEW
Checked Open Submissions Checked Indexed Checked Peer Reviewed
NEW DRUGS AND HEALTH TECHNOLOGIES
Checked Open Submissions Checked Indexed Checked Peer Reviewed
ORPHAN DRUGS AND DISEASES
Checked Open Submissions Checked Indexed Checked Peer Reviewed
OBSTETRICS AND GYNECOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
IMMUNOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
ANESTHESIOLOGY AND RESUSCITATION
Checked Open Submissions Checked Indexed Checked Peer Reviewed
HEMATOLOGY AND TRANSFUSIOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
GERONTOLOGY AND GERIATRICS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
INTERNAL MEDICINE
Checked Open Submissions Checked Indexed Checked Peer Reviewed
DERMATOVENEROLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PEDIATRIC SURGERY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
INFECTIOUS DISEASES
Checked Open Submissions Checked Indexed Checked Peer Reviewed
CARDIOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
CLINICAL LABORATORY DIAGNOSIS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
DENTISTRY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PHARMACOLOGY, CLINICAL PHARMACOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
RADIATION DIAGNOSTICS AND THERAPY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
MEDICAL CYBERNETICS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PSYCHIATRY AND NARCOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
NEUROLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
NEPHROLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PUBLIC HEALTH AND HEALTHCARE
Checked Open Submissions Checked Indexed Checked Peer Reviewed
ONCOLOGY, RADIATION THERAPY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
OPHTHALMOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
OTORHINOLARYNGOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PALLIATIVE CARE
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PEDIATRICS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PLASTIC SURGERY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PULMONOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
RHEUMATOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
CARDIOVASCULAR SURGERY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
TRAUMATOLOGY AND ORTHOPEDICS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
UROLOGY AND ANDROLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PHYSICAL AND REHABILITATION MEDICINE
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PHTHISITRY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
SURGERY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
ENDOCRINOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
EPIDEMIOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
DRUG PROVISION
Checked Open Submissions Checked Indexed Checked Peer Reviewed
MANAGEMENT AND ECONOMICS OF PHARMACY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
DRUG SAFETY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
MEDICAL DEVICE SAFETY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
BIOMEDICAL ETHICS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
DRUG INTERACTIONS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
QUALITY OF LIFE
Checked Open Submissions Checked Indexed Checked Peer Reviewed
DRUGS UTILIZATION RESEARCH
Checked Open Submissions Checked Indexed Checked Peer Reviewed
REAL-WORLD STUDIES
Checked Open Submissions Checked Indexed Checked Peer Reviewed
CLINICAL TRIALS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
HEALTH TECHNOLOGY ASSESSMENT
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PERSONALIZED MEDICINE
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PHARMACOGENETICS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PHARMACOVILIGANCE
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PHARMACOECONOMICS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PHARMACOEPIDEMIOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PRACTICAL RECOMMENDATIONS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
EXPERT OPINIONS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
SOFTWARE
Checked Open Submissions Checked Indexed Checked Peer Reviewed
EDUCATION
Checked Open Submissions Checked Indexed Checked Peer Reviewed
HISTORY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
BOOKSHELF
Checked Open Submissions Checked Indexed Checked Peer Reviewed
MESSAGE FROM COMPANY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
ANNIVERSARY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
IN MEMORIAL
Checked Open Submissions Checked Indexed Checked Peer Reviewed
SYSTEMATIC REVIEW AND META-ANALYSIS
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PSYCHOTHERAPY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
UROLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
RATIONAL PHARMACOTHERAPY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
BOOK REVIEW
Checked Open Submissions Checked Indexed Checked Peer Reviewed
HISTORY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PHARMACOGNOSY AND PHARMACEUTICAL TECHNOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
OBITUARY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PHARMACEUTICAL CHEMISTRY, PHARMACOGNOSY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
PHARMACY BUSINESS ORGANIZATION
Checked Open Submissions Checked Indexed Checked Peer Reviewed
FORENSIC MEDICINE
Checked Open Submissions Checked Indexed Checked Peer Reviewed
DIGITAL MEDICINE
Checked Open Submissions Checked Indexed Checked Peer Reviewed
CLINICAL PHARMACOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
CLINICAL PSYCHOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
ONCOLOGY
Checked Open Submissions Checked Indexed Checked Peer Reviewed
HYGIENE
Checked Open Submissions Checked Indexed Checked Peer Reviewed
 

Peer Review Process

All scientific articles submitted to the editors of the journal "Patient-Oriented Medicine and Pharmacy" undergo mandatory two-sided anonymous (“blind”) peer review (the authors of the manuscript do not know the reviewers and receive a letter with comments signed by the editor-in-chief or scientific editor).

Articles reviewed by invited reviewers - leading experts in the relevant fields of medicine and pharmacy in Russia and other countries. The decision to choose one or another reviewer for the examination of the article is made by the editor-in-chief, deputy editor-in-chief, scientific editor, editorial manager. The review period is 8 weeks, but at the request of the reviewer, it can be extended.

Each article is sent to 2 reviewers.

Each reviewer has the right to refuse a review if there is a clear conflict of interest that affects the perception and interpretation of the manuscript material. Based on the results of reviewing the manuscript, the reviewer makes recommendations on the future fate of the article (each decision of the reviewer is justified):

  • The article is recommended for publication in its present form;
  • The article is recommended for publication after the shortcomings noted by the reviewer are corrected;
  • The article needs additional review by another specialist;
  • This article cannot be published in a journal.

If the review contains recommendations for correcting and refining the article, the editors of the journal send the author the text of the review with a proposal to take them into consideration when preparing a new version of the article or to refute them with reason (partially or completely). Finalization of the article should not take more than two months from the date of e-mailing the authors about the need to make changes. This article modified by the author is re-sent for review.

If the authors refuse to finalise the materials, they must notify the editors in writing or orally of their refusal to publish the article. If the authors do not return the revised version after 3 months from the date of sending the review, even in the absence of information from the authors with a refusal to finalise the article, the editors remove it from the register. In such situations, the authors are sent a corresponding notice of the removal of the manuscript from registration due to the expiration of the time allotted for revision.

If the author and reviewers have irresolvable contradictions regarding the manuscript, the editorial board has the right to send the manuscript for additional review. In conflict situations, the decision is made by the editor-in-chief at a meeting of the editorial board.

The decision to refuse the publication of the manuscript was made at a meeting of the editorial board in accordance with the recommendations of the reviewers. An article not recommended by the decision of the editorial board for publication is not accepted for re-consideration. A notice of refusal to publish was sent to the author by e-mail.

After the editorial board of the journal decides on the admission of the article for publication, the editorial board informs the author about this and indicates the terms of publication.

The presence of a positive review is not sufficient grounds for publishing an article. The final decision on publication is made by the editorial board. In conflict situations, the decision is made by the editor-in-chief.

The original reviews are stored in the editorial office of the journal for 5 years.

 

Publication Frequency

The journal "Patient-Oriented Medicine and Pharmacy" publishes 4 issues per year. Articles in each issue are distributed as they are ready and in the order they are received by the editorial board.

 

Open Access Policy

This is an open access journal. All articles are made freely available to readers immediatly upon publication.

Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition - it means that articles have free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself.

For more information please read BOAI statement.

 

 

Archiving

  • National Electronic Information Consortium (NEICON)​​​​​​​
  • Russian Scientific Electronic Library
  • Elibrary
  • CyberLeninka
  • RSL Russian State Library

 

Peer-Review

A double-blind peer review method is mandatory for processing of all scientific manuscripts submitted to the editorial stuff of "Patient-Oriented Medicine and Pharmacy". This implies that neither the reviewer is aware of the authorship of the manuscript, nor the author maintains any contact with the reviewer. The manuscripts are sent to two reviewers for evaluation.

  1. Leading Russian and international experts in corresponding areas of life sciences, invited as independent readers, perform peer reviews. Editor-in-chief, deputy editor-in-chief or science editor choose readers for peer review. We aim to limit the review process to 8 weeks, though in some cases the schedule may be adjusted at the reviewer’s request.
  2. Reviewer has an option to abnegate the assessment should any conflict of interests arise that may affect perception or interpretation of the manuscript. Upon the scrutiny, the reviewer is expected to present the editorial board with one of the following recommendations:
    - to accept the paper in its present state;
    - to invited the author to revise their manuscript to address specific concerns before final decision is reached;
    - that final decision be reached following further reviewing by another specialist;
    - to reject the manuscript outright.
  3. If the reviewer has recommended any refinements, the editorial staff would suggest the author either to implement the corrections, or to dispute them reasonably. Authors are kindly required to limit their revision to 2 months and resubmit the adapted manuscript within this period for final evaluation.
  4. We politely request that the editor be notified verbally or in writing should the author decide to refuse from publishing the manuscript. In case the author fails to do so within 3 months since receiving a copy of the initial review, the editorial board takes the manuscript off the register and notifies the author accordingly.
  5. If author and reviewers meet insoluble contradictions regarding revision of the manuscript, the editor-in-chief resolves the conflict by his own authority.
  6. The editorial board reaches final decision to reject a manuscript on the hearing according to reviewers’ recommendations, and duly notifies the authors of their decision via e-mail. The board does not accept previously rejected manuscripts for re-evaluation.
  7. Upon the decision to accept the manuscript for publishing, the editorial staff notifies the authors of the scheduled date of publication.
  8. Kindly note that positive review does not guarantee the acceptance, as final decision in all cases lies with the editorial board. By his authority, editor-in-chief rules final solution of every conflict.
  9. Original reviews of submitted manuscripts remain deposited for 5 years.

 

Publishing Ethics

The Publication Ethics and Publication Malpractice Statement of the journal "Patient-Oriented Medicine and Pharmacy" are based on the Committee on Publication Ethics (COPE) Code of Conduct guidelines available at www.publicationethics.org,  and requirements for peer-reviewed journals, elaborated by the "Elsevier" Publishing House (in accordance with international ethical rules of scientific publications)

The Publication Ethics and Publication Malpractice Statement of the journal "Patient-Oriented Medicine and Pharmacy" are based on the Committee on Publication Ethics (COPE) Code of Conduct guidelines available at www.publicationethics.org,  and requirements for peer-reviewed medical journals ((http://health.elsevier.ru/attachments/editor/file/ethical_code_final.pdf), elaborated by the "Elsevier" Publishing House (in accordance with international ethical rules of scientific publications) 

1. Introduction

1.1. The publication in a peer reviewed learned journal, serves many purposes outside of simple communication. It is a building block in the development of a coherent and respected network of knowledge. For all these reasons and more it is important to lay down standards of expected ethical behaviour by all parties involved in the act of publishing: the author, the journal editor, the peer reviewer, the publisher and the society for society-owned or sponsored journal: "Patient-Oriented Medicine and Pharmacy"

1.2.Publisher has a supporting, investing and nurturing role in the scholarly communication process but is also ultimately responsible for ensuring that best practice is followed in its publications.

1.3. Publisher takes its duties of guardianship over the scholarly record extremely seriously. Our journal programmes record «the minutes of science» and we recognise our responsibilities as the keeper of those «minutes» in all our policies not least the ethical guidelines that we have here adopted.

2. Duties of Editors

2.1.Publication decision – The Editor of a learned "Patient-Oriented Medicine and Pharmacy" is solely and independently responsible for deciding which of the articles submitted to the journal should be published, often working on conjunction with the relevant society (for society-owned or sponsored journals). The validation of the work in question and its importance to researchers and readers must always underwrite such decisions. The Editor may be guided by the policies of the "Patient-Oriented Medicine and Pharmacy" journal’s editorial board and constrained by such legal requirements as shall then be in force regarding libel, copyright infringement and plagiarism. The editor may confer with other editors or reviewers (or society officers) in making this decision.

2.2.Fair play – An editor should evaluate manuscripts for their intellectual content without regard to race, gender, sexual orientation, religious belief, ethnic origin, citizenship, or political philosophy of the authors.

2.3.Confidentiality – The editor and any editorial staff of "Patient-Oriented Medicine and Pharmacy" must not disclose any information about a submitted manuscript to anyone other than the corresponding author, reviewers, potential reviewers, other editorial advisers, and the publisher, as appropriate.

2.4.Disclosure and Conflicts of interest

2.4.1. Unpublished materials disclosed in a submitted manuscript must not be used in an editor’s own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage.

2.4.2. Editors should recuse themselves (i.e. should ask a co-editor, associate editor or other member of the editorial board instead to review and consider) from considering manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or (possibly) institutions connected to the papers.

2.5.Vigilance over published record – An editor presented with convincing evidence that the substance or conclusions of a published paper are erroneous should coordinate with the publisher (and/or society) to promote the prompt publication of a correction, retraction, expression of concern, or other note, as may be relevant.

2.6.Involvement and cooperation in investigations – An editor should take reasonably responsive measures when ethical complaints have been presented concerning a submitted manuscript or published paper, in conjunction with the publisher (or society). Such measures will generally include contacting the author of the manuscript or paper and giving due consideration of the respective complaint or claims made, but may also include further communications to the relevant institutions and research bodies.

3.    Duties of Reviewers

3.1.Contribution to Editorial Decisions – Peer review assists the editor in making editorial decisions and through the editorial communications with the author may also assist the author in improving the paper. Peer review is an essential component of formal scholarly communication, and lies at the heart of the scientific method. Publisher shares the view of many that all scholars who wish to contribute to publications have an obligation to do a fair share of reviewing.

3.2.Promptness – Any selected referee who feels unqualified to review the research reported in a manuscript or knows that its prompt review will be impossible should notify the editor of "Patient-Oriented Medicine and Pharmacy" and excuse himself from the review process.

3.3.Confidentiality – Any manuscripts received for review must be treated as confidential documents. They must not be shown to or discussed with others except as authorised by the editor.

3.4.Standard and objectivity – Reviews should be conducted objectively. Personal criticism of the author is inappropriate. Referees should express their views clearly with supporting arguments.

3.5.Acknowledgement of Sources – Reviewers  should identify relevant published work that has not been cited by the authors. Any statement that an observation, derivation, or argument had been previously reported should be accompanied by the relevant citation. A reviewer should also call to the editor’s attention any substantial similarity or overlap between the manuscript under consideration and any other published paper of which they have personal knowledge.

3.6.Disclosure and Conflict of Interest

3.6.1.Unpublished materials disclosed in a submitted manuscript must not be used in a reviewer’s own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage.

3.6.2. Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.

4. Duties of Authors

4.1.Reporting standards

4.1.1. Authors of reports of original research should present an accurate account of the work performed as well as an objective discussion of its significance. Underlying data should be represented accurately in the paper. A paper should contain sufficient detail and references to permit others to replicate the work. Fraudulent or knowingly inaccurate statements constitute unethical behaviour and are unacceptable.

4.1.2. Review and professional publication articles should also be accurate and objective, and editorial 'opinion’ works should be clearly identified as such.

4.2.Data Access and Retention – Authors may be asked to provide the raw data in connection with a paper for editorial review, and should be prepared to provide public access to such data (consistent with the ALPSP-STM Statement on Data and Databases), if practicable, and should in any event be prepared to retain such data for a reasonable time after publication.

4.3.Originality and Plagiarism

4.3.1. The authors should ensure that they have written entirely original works, and if the authors have used the work and/or words of others, this has been appropriately cited or quoted.

4.3.2. Plagiarism takes many forms, from ‘passing off’ another’s paper as the author’s own paper, to copying or paraphrasing substantial parts of another’s paper (without attribution), to claiming results from research conducted by others. Plagiarism in all its forms constitutes unethical publishing behaviour and is unacceptable.

4.4.Multiple, Redundant or Concurrent Publication

4.4.1. An author should not in general publish manuscripts describing essentially the same research in more than one journal of primary publication. Submitting the same manuscript to more than one journal concurrently constitutes unethical publishing behaviour and is unacceptable.

4.4.2. In general, an author should not submit for consideration in another journal a previously published paper.

4.4.3. Publication of some kinds of articles (eg, clinical guidelines, translations) in more than one journal is sometimes justifiable, provided certain conditions are met. The authors and editors of the journals concerned must agree to the secondary publication, which must reflect the same data and interpretation of the primary document. The primary reference must be cited in the secondary publication. Further detail on acceptable forms of secondary publication can be found at www.icmje.org.

4.5.Acknowledgement of Sources – Proper acknowledgment of the work of others must always be given. Authors should cite publications that have been influential in determining the nature of the reported work. Information obtained privately, as in conversation, correspondence, or discussion with third parties, must not be used or reported without explicit, written permission from the source. Information obtained in the course of confidential services, such as refereeing manuscripts or grant applications, must not be used without the explicit written permission of the author of the work involved in these services.

4.6.Authorship of the Paper

4.6.1. Authorship should be limited to those who have made a significant contribution to the conception, design, execution, or interpretation of the reported study. All those who have made significant contributions should be listed as co-authors. Where there are others who have participated in certain substantive aspects of the research project, they should be acknowledged or listed as contributors.

4.6.2. The corresponding author should ensure that all appropriate co-authors and no inappropriate co-authors are included on the paper, and that all co-authors have seen and approved the final version of the paper and have agreed to its submission for publication.

4.7.Hazards and Human or Animal Subjects

4.7.1. If the work involves chemicals, procedures or equipment that have any unusual hazards inherent in their use, the author must clearly identify these in the manuscript.

4.7.2. If the work involves the use of animal or human subjects, the author should ensure that the manuscript contains a statement that all procedures were performed in compliance with relevant laws and institutional guidelines and that the appropriate institutional committee(s) have approved them. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

4.8. Disclosure and Conflicts of Interest

4.8.1. All authors should disclose in their manuscript any financial or other substantive conflict of interest that might be construed to influence the results or interpretation of their manuscript. All sources of financial support for the project should be disclosed.

4.8.2. Examples of potential conflicts of interest which should be disclosed include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Potential conflicts of interest should be disclosed at the earliest possible stage.

4.9. Fundamental errors in published works – When an author discovers a significant error or inaccuracy in a published work, it is the author’s obligation to promptly notify the editor of "Patient-Oriented Medicine and Pharmacy" journal and cooperate with Publisher to retract or correct the paper, If the editor or the publisher learn from a third party that a published work contains a significant error, it is the obligation of the author to promptly retract or correct the paper.

5. Duties of the Publisher (and if relevant, Society)

5.1. Publisher should adopt policies and procedures that support editors, reviewers and authors of "Patient-Oriented Medicine and Pharmacy" in performing their ethical duties under these ethics guidelines. The publisher should ensure that the potential for advertising or reprint revenue has no impact or influence on editorial decisions.

5.2. The publisher should support "Patient-Oriented Medicine and Pharmacy" journal editors in the review of complaints raised concerning ethical issues and help communications with other journals and/or publishers where this is useful to editors.

5.3. Publisher should develop codes of practice and inculcate industry standards for best practice on ethical matters, errors and retractions.

5.4. Publisher should provide specialised legal review and counsel if necessary.

The section is prepared according to the files (http://health.elsevier.ru/attachments/editor/file/ethical_code_final.pdf) of Elsevier publisher (https://www.elsevier.com/) and files (http://publicationethics.org/resources) from Committee on Publication Ethics (COPE - http://publicationethics.org/). 

 

 

Founder

 

Article processing charge

Since Jule 1, 2026, publication of scientific articles in the journal "Patient-Oriented Medicine and Pharmacy" is subject to a fee and is subject to payment of an article processing charge (APC). This fee covers the process of updating submitted manuscripts to international guidelines for authors, a process that requires significant editorial time and resources. Thanks to the APC, all articles published in the journal are openly accessible immediately after publication. The APC covers scientific editing, technical editing and proofreading, article layout, website posting, indexed databases and repositories, and author engagement.

Free article publication. High-quality articles (research of national or international standing) may be eligible for free publication at the discretion of the editorial board. We review requests for exceptions to the rules and make individual decisions on a case-by-case basis. In particular, the article processing fee is waived for the sole author of an article who is a graduate student at a Russian state university. In this case, a cover letter—a publication referral from the research institution on the institution's letterhead and signed by an official—is required. Please submit your request for an exception to these guidelines when submitting your manuscript. A decision is typically made within two business days. Requests submitted after the initial review or during the peer review process will not be considered.

Before submitting your article to the editor, please read not only the Author Guidelines but also the editorial and publishing fee terms.

Payment of the editorial and publishing fee is made after the article has been reviewed and accepted for publication by the journal's editorial board by transferring funds to the bank account of OKI Publishing House LLC. The article must not be advertising in nature and must not contain trade names of drugs or medical devices, nor information about grant support or other forms of funding.

Publication of scientific articles in the journal "Patient-Oriented Medicine and Pharmacy" is subject to payment of the editorial and publishing fee of 15,000 rubles per article.

To pay the editorial and publishing fee as an individual, please follow the link: Payment of the editorial and publishing fee in the journal "Patient-Oriented Medicine and Pharmacy."

As confirmation of payment, you will receive a receipt from Yandex OFD to the email address you provided. This is an official document that can be submitted to your organization's accounting department for reimbursement of expenses.

After payment, please notify the editorial staff by email at eva88@list.ru, indicating the title of the publication, and your article will be sent for further processing and preparation for publication.

These rates are for individuals only, provided payment is made by credit card. Payment by legal entities is subject to different terms; it is also possible that an agreement between the legal entity and the publisher has already been concluded. If authors intend to make payment from a legal entity's account, please indicate this when submitting the manuscript. To pay from a legal entity, please send a request and the organization's bank details to eva88@list.ru to receive an invoice for the editorial and publishing fee. After you provide a copy of the payment receipt to the editorial staff, the article will be sent for further processing and preparation for publication.

Payment for retracted articles is non-refundable.

__________________

Fast Track Publication. After the manuscript has been peer-reviewed and accepted for publication by the editors, it will be published in the next issue of the journal. This service includes the following:

  • Technical preparation of the manuscript for peer review.
  • Expedited peer review.
  • Publication in electronic format online on the journal's website in the "Accepted for publication" section ("Online First").
  • Priority publication in the next upcoming issue of the journal.

The fee for this service is 25,000 (twenty five thousand) rubles per work.

Payment procedure: After the manuscript has successfully passed the peer-review stage ("recommended for publication"), the editor sends the corresponding author a letter with the results. While the manuscript is being revised based on the reviewers' and editor's comments, the author can notify the editors of their choice of the "Expedited Publication" service and make payment. Upon receipt of payment, the article approved by the editors and corresponding author is posted in PDF format on the journal's website in the "Online First" section prior to publication in the print issue, and is also included in the next upcoming print issue. The service is considered rendered upon publication of the print issue containing the authors' article.

To pay for urgent publication ("Fast Track") by an individual, please follow the link below:
Fast Track fee for publishing an article in the journal "Patient-Oriented Medicine and Pharmacy."

__________________

This offer is a public offer.

June 16, 2026, Moscow

 

Disclosure and Conflict of Interest

Unpublished materials disclosed in a submitted manuscript must not be used in a reviewer’s own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage.

Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.

 

Plagiarism detection

"Patient-Oriented Medicine and Pharmacy" use native russian-language plagiarism detection software Antiplagiat to screen the submissions. If plagiarism is identified, the COPE guidelines on plagiarism will be followed.

 

Preprint and postprint Policy

Prior to acceptance and publication in "Patient-Oriented Medicine and Pharmacy", authors may make their submissions available as preprints on personal or public websites.

As part of submission process, authors are required to confirm that the submission has not been previously published, nor has been submitted. After a manuscript has been published in "Patient-Oriented Medicine and Pharmacy" we suggest that the link to the article on journal's website is used when the article is shared on personal or public websites.

Glossary (by SHERPA)

Preprint - In the context of Open Access, a preprint is a draft of an academic article or other publication before it has been submitted for peer-review or other quality assurance procedure as part of the publication process. Preprints cover initial and successive drafts of articles, working papers or draft conference papers.
 
Postprint - The final version of an academic article or other publication - after it has been peer-reviewed and revised into its final form by the author. As a general term this covers both the author's final version and the version as published, with formatting and copy-editing changes in place.

 

Revenue Sources

The publication of the journal is financed by the funds of the parent organization, at the expense of the publisher, publication of advertising materials, publication of reprints, article processment charges.

 

Policy on revocation or correction of articles

Editors should consider retracting a publication if:

  • They have clear evidence that the findings are unreliable, either as a result of major error (eg, miscalculation or experimental error), or as a result of fabrication (eg, of data) or falsification (eg, image manipulation)
  • It constitutes plagiarism
  • The findings have previously been published elsewhere without proper attribution to previous sources or disclosure to the editor, permission to republish, or justification (ie, cases of redundant publication)
  • It contains material or data without authorisation for use
  • Copyright has been infringed or there is some other serious legal issue (eg, libel, privacy)
  • It reports unethical research
  • It has been published solely on the basis of a compromised or manipulated peer review process
  • The author(s) failed to disclose a major competing interest (a.k.a. conflict of interest) that, in the view of the editor, would have unduly affected interpretations of the work or recommendations by editors and peer reviewers.

Notices of retraction should:

  • Be linked to the retracted article wherever possible (ie, in all online versions)
  • Clearly identify the retracted article (eg, by including the title and authors in the retraction heading or citing the retracted article)
  • Be clearly identified as a retraction (ie, distinct from other types of correction or comment)
  • Be published promptly to minimise harmful effects
  • Be freely available to all readers (ie, not behind access barriers or available only to subscribers)
  • State who is retracting the article
  • State the reason(s) for retraction
  • Be objective, factual and avoid inflammatory language.

Retractions are not usually appropriate if:

  • The authorship is disputed but there is no reason to doubt the validity of the findings
  • The main findings of the work are still reliable and correction could sufficiently address errors or concerns
  • An editor has inconclusive evidence to support retraction, or is awaiting additional information such as from an institutional investigation (for information about Expressions of Concern see https://publicationethics.org/expressions-of-concern-forum-discussion)
  • Author conflicts of interest have been reported to the journal after publication, but in the editor’s view these are not likely to have influenced interpretations or recommendations or the conclusions of the article.

For more information: COPE (Version 2: November 2019)

https://publicationethics.org/files/retraction-guidelines.pdf 

 

Policy on the Processing and Protection of Personal Data

1. General Provisions

1.1. This document defines the position of OOO "Izdatelstvo OKI" (Primary State Registration Number 1037721010788, Taxpayer Identification Number 7721253233, Reason for Registration Code 773101001, hereinafter referred to as the "Operator") regarding compliance with the requirements of the legislation of the Russian Federation on personal data (Federal Law No. 152-FZ of July 27, 2006 "On Personal Data"), as well as the procedure for the processing and protection of information pertaining to individuals (Users) utilizing the Operator's Websites.

1.2. Legislative Changes in 2025–2026: This Policy has been updated to incorporate:

  • The entry into force of Order No. 140 of the Federal Service for Supervision of Communications, Information Technology and Mass Media (Roskomnadzor) dated June 19, 2025 (new requirements for data depersonalization/anonymization).

  • The mandatory requirement for separate consent for the processing of personal data (Part 1, Article 9 of Federal Law No. 152-FZ).

  • The obligation for localisation of databases on the territory of the Russian Federation.

1.3. The use of the Operator's Websites by the User constitutes unconditional acceptance of the terms of this Policy.

2. Legal Bases for Processing

2.1. The Operator processes personal data exclusively on the following legal bases:

  • Federal Law No. 152-FZ "On Personal Data".

  • Federal Law No. 149-FZ "On Information, Information Technologies and the Protection of Information".

  • Separate informed consent of the User (executed as a standalone document and not as an integral part of a user agreement).

3. Composition of Personal Data

3.1. During registration, subscription, or the use of feedback forms on the Websites (www.izdat-oki.ru and others), the Operator may process:

  • Mandatory Data: Surname, first name, patronymic name, email address.

  • Optional Data: Contact telephone number, place of employment, position, academic degree.

  • Other Data (depersonalized): Cookie data, IP address, browser information. In accordance with the requirements of Order No. 140, automatically collected data is subject to depersonalization/anonymization using methods of identifier introduction or semantic modification.

4. Purposes of Processing

4.1. The Operator collects data strictly for the achievement of the following purposes (principle of data minimization):

  • Provision of electronic journals, news, and publication notifications via mailing lists.

  • Conclusion and execution of agreements (including public offers).

  • Communication with authors and reviewers.

  • Improvement of website functionality (analytics, statistics).

5. Requirements for Depersonalization/Anonymization

5.1. In accordance with Order No. 140 of Roskomnadzor (effective from September 1, 2025), the Operator ensures the depersonalization/anonymization of personal data using the following methods:

  • Identifier Introduction Method: Replacement of full names and contact details with unique codes (IDs) for internal analytics.

  • Transformation Method: Aggregation/generalization of data for statistical reporting.

5.2. The storage of source (original) and depersonalized/anonymized data is carried out separately. Access to de-identification keys (using the identifier introduction method) is restricted solely to authorized personnel.

6. Localisation and Storage (Compliance with Federal Law No. 152-FZ)

6.1. Recording, systematisation, accumulation, and storage of personal data of Russian Users are carried out using server infrastructure located within the territory of the Russian Federation.

6.2. The retention periods for personal data correspond to the purposes of their processing and shall not exceed the durations stipulated by the applicable legislation of the Russian Federation. Upon withdrawal of consent or achievement of the processing purposes, data is subject to destruction.

7. Consent to Processing

7.1. The User provides consent for the processing of their data freely, by their own will, and in their own interest.

7.2. Form of Consent: Consent is executed via a separate action (through a checkbox or explicit confirmation in a distinct window) and does not constitute a tacit condition of any agreement. The User has the right to withdraw consent by sending a written notification to the Operator's email address.

8. Transfer of Data to Third Parties

8.1. The Operator is entitled to transfer personal data to third parties solely under the following circumstances:

  • The User has explicitly expressed consent to such transfer.

  • The transfer is mandated by the legislation of the Russian Federation.

  • The transfer occurs within the framework of data processing by authorized partners (e.g., email distribution services, hosting providers) subject to the conclusion of agreements with them that contain confidentiality obligations.

8.2. Cross-Border Transfer: Should a Website be technically accessible from abroad, the Operator hereby notifies that cross-border transfer of personal data is carried out only upon obtaining a corresponding notification from Roskomnadzor and subject to ensuring legal protection for such data.

9. Rights of the Personal Data Subject

9.1. The User has the right to:

  • Obtain information regarding the processing of their data.

  • Request rectification, blocking, or destruction of their inaccurate data.

  • Withdraw consent for data processing.

  • Appeal against the Operator's actions to Roskomnadzor.

10. Liability and Dispute Resolution

10.1. The Operator shall bear no liability for the actions of third parties who gain access to the User's data through websites to which hyperlinks from the Operator's resources lead.

10.2. Disputes shall be subject to adjudication in a court of law at the Operator's place of location in accordance with the applicable legislation of the Russian Federation.

11. Operator's Details

OOO "Izdatelstvo OKI"
Postal Address: 121357, Moscow, st. Vatutina, 4, building 2, apt. 22
Email for Requests from Personal Data Subjects: eva88@list.ru

OOO "Izdatelstvo OKI"

Date of Publication: October 8, 2024
Effective Date: January 1, 2026
Current Version: No. 2 dated May 10, 2026 (superseding the version of October 8, 2024)

 

Policy on the Use of Artificial Intelligence Services

This Policy governs the use of artificial intelligence (hereinafter — AI) services by authors, reviewers, and editors at all stages of the publishing process: manuscript writing, peer review, and editorial preparation. The Journal recognizes that generative and other AI tools may serve as useful aids but cannot replace scientific expertise, critical thinking, or authorial responsibility. The purpose of this Policy is to uphold the principles of academic transparency and ethics in scientific publishing.

  1. Scope

This Policy applies to all articles except those directly devoted to artificial intelligence, where AI services are the subject of description or illustration of the manuscript’s content.

  1. General Principles
  • AI is not and cannot be listed as a co‑author. AI tools (including language models, image generation systems, code generators, etc.) shall not be included in the author or co‑author byline.
  • Authors shall not delegate to AI the authority to make scientifically significant decisions (such as hypothesis formation, result interpretation, conclusions, and recommendations) without their own critical oversight.
  • Responsibility for the content of the manuscript—including text, data, figures, code, and references—always lies fully with the named authors. Authors are required to thoroughly verify and edit the manuscript prior to submission to the editorial office, including the bibliography and accuracy of citations.
  1. Disclosure of AI Use

Any substantial use of generative AI in the preparation of a manuscript must be explicitly disclosed in a separate section (e.g., “Section on disclosure of AI use”, within the “Acknowledgments” subsection, or “Statement on AI use”) with a brief description of:

  • which specific tools were used (name, version/model, provider);
  • at which stage and for what purpose (e.g., “language editing of the Discussion section”, “assistance in structuring the Introduction”).

Example wording: “In the preparation of this article, the following AI services were used: [name, version/model] for [purpose]. All outputs have been verified by the authors; no confidential or previously unpublished data were uploaded to public services.”

Grammar, spelling, and punctuation checks, as well as translation of manuscript excerpts into a foreign language, do not require disclosure.

Disclosure of AI use does not relieve authors of responsibility for the completeness, accuracy, and integrity of the data and conclusions presented.

  1. Permissible Use of AI

AI may be used as an auxiliary tool for:

  • language editing and stylistic improvement of already written text;
  • assistance in structuring material, formulating titles and abstracts;
  • spell‑checking, grammar checking, and basic formatting;
  • technical assistance in preparing cover letters.

In all cases, authors are required to carefully verify and, if necessary, correct the outputs of AI, avoiding factual errors, distortion of meaning, plagiarism, or incorrect references. Authors must retain a trace of use (prompts/scripts/parameters) and provide it to the editorial office upon request.

  1. Impermissible Use of AI

AI use is strictly prohibited for:

  • generating, modifying, or “enhancing” research data, images, diagrams, or code that are presented as actual research results;
  • fabricating, falsifying, or concealing data, as well as creating “mock” data instead of empirically obtained results;
  • writing substantive sections of the manuscript without author involvement (generating text that is presented as entirely original scholarly contribution without substantial revision and verification by the authors);
  • automatic selection, invention, or distortion of bibliographic references;
  • preparing or substantively editing illustrative material (data visualizations), except for color correction that does not alter the content;
  • circumventing peer review procedures, simulating reviews, or presenting others’ ideas as one’s own.
  1. Responsibilities of Reviewers and Editorial Board Members

Reviewers, editorial board members, and employees of OKI Publishing LLC may use AI tools only in exceptional cases as an auxiliary means for language editing of their own review text, subject to the following conditions:

  • full preservation of confidentiality of the manuscript and review (strictly prohibited is uploading the manuscript, its fragments, illustrations, tables, unpublished data, or parts of the review to public AI services);
  • complete personal control over the content, tone, and correctness of the review.

The use of AI to automatically generate reviews or decisions on a manuscript is not permitted. An exception is made for plagiarism detection systems operated under an agreement with aggregators that ensures the confidentiality of manuscript texts.

  1. Confidentiality, Data, and Copyright

When using AI, authors, reviewers, and editors are obliged to:

  • not upload confidential or personal data to public AI services without a corresponding legal basis and consent (a public AI service means an external online platform where the provider may store or use the input data);
  • respect copyright and third‑party rights, and not use AI to create derivative works that infringe intellectual property rights.

Authors are responsible for ensuring that all illustrations, tables, and other materials created with the involvement of AI do not violate third‑party rights and comply with the Journal’s requirements regarding ethics and copyright.

  1. Violations and Consequences

Violation of this Policy shall be treated as a potential breach of publication ethics (including data fabrication, plagiarism, concealment of information, or misleading the editorial office and readers). Depending on the severity of the violation, the Journal may take measures ranging from requesting clarifications and correcting the manuscript to rejection, retraction of a published article, and notification of the authors’ institutions or relevant ethics committees.

  1. Effective Date and Revision

This Policy is regularly reviewed and updated in light of the development of AI services and evolving standards of publication ethics.

Version 2, dated 28 April 2026.

 

Authorship Policy and Contribution Statement

The journal adheres to strict principles of research ethics and follows international standards (ICMJE, COPE) in determining authorship and contributor roles.

Authorship Criteria

To be listed as an author, one must have made a significant intellectual contribution to the study, including:

  • Participation in research conception and design.
  • Data collection, analysis, or interpretation.
  • Drafting or critically revising the manuscript.
  • Approval of the final version for publication.

The following do not qualify for authorship:

  • Funding acquisition alone.
  • Provision of materials or technical assistance only.
  • General supervision without direct scientific input.

Authorship Order

  • Author order should reflect relative contributions (first author = primary researcher, last author = senior supervisor).
  • All authors must approve the submitted manuscript and take responsibility for its content.
  • Changes to the author list after submission require written consent from all authors and editorial approval.

Author Responsibilities

Each author must:

  • Disclose their specific contributions (using CRediT – Contributor Roles Taxonomy).
  • Justify the inclusion of all co-authors and explain any omissions.
  • Cooperate in resolving authorship disputes.

Special Cases

  • Group authorship (consortia, collaborations) – must specify the group’s role and a contact person.
  • Non-author contributors (e.g., statistical support) – should be acknowledged in the "Acknowledgements" section with their consent.

Disputes and Violations

  • Authorship disputes will be investigated by the editorial board (drafts, correspondence, or lab records may be requested).
  • Unjustified inclusion/exclusion of authors may lead to manuscript rejection or retraction.
  • "Guest" or "gift" authorship (adding non-contributors) is prohibited and considered unethical.

Contribution Statement

Upon submission, authors must complete a "Contributor Roles" form (e.g., following CRediT standards), detailing:

  • Conceptualization – Idea formulation; overarching research goals.
  • Data Curation – Managing, annotating, and archiving research data.
  • Formal Analysis – Applying statistical/mathematical/computational techniques.
  • Funding Acquisition – Securing financial support for the project.
  • Investigation – Conducting experiments/data collection.
  • Methodology – Designing research methods and protocols.
  • Project Administration – Overseeing research planning and execution.
  • Resources – Providing materials, tools, or infrastructure.
  • Software – Developing, programming, or testing software.
  • Supervision – Leading and mentoring the research team.
  • Validation – Verifying reproducibility and accuracy of results.
  • Visualization – Preparing figures, diagrams, or presentations.
  • Writing – Original Draft – Creating the first manuscript version.
  • Writing – Review & Editing – Revising and refining the manuscript.

These roles help clarify individual contributions in multi-author papers, improving transparency in academic publishing. The journal reserves the right to request additional clarification on authorship at any stage of peer review.

This policy aligns with ICMJE (International Committee of Medical Journal Editors) and COPE (Committee on Publication Ethics) guidelines.

 

Complaints and Appeals Policy

The journal is committed to maintaining fairness, transparency, and objectivity in handling all complaints and appeals. This policy follows COPE (Committee on Publication Ethics) guidelines and international standards of scholarly publishing.

Types of Complaints Considered

The journal will review:

  • Appeals of editorial decisions (rejection, revision requests)
  • Allegations of publication ethics violations
  • Concerns about peer review quality
  • Conflicts between authors, reviewers, and editors
  • Accusations of plagiarism or data fabrication

Submission Process

  1. Complaints must be sent to the Editor-in-Chief via the journal's official email: clinvest@mail.ru.
  2. The complaint should include:
  • Manuscript ID (number) in the publication system, article title, article authors (if applicable)
  • Detailed description of the issue
  • Supporting evidence and materials
  • Complainant's contact information

Review Procedure

Initial Assessment (3 business days):

  • Acknowledgement of receipt
  • Evaluation of complaint validity

Formal Investigation (15-30 business days):

  • Formation of an independent review panel
  • Collection of additional information
  • Comprehensive case examination

Decision Making:

  • Panel reaches a conclusion
  • All parties receive notification
  • Retraction may be initiated for serious violations

Possible Outcomes

  • Reversal of publication decision
  • Additional peer review
  • Publication of corrections/retractions
  • Article retraction
  • Temporary or permanent bans for violators

Special Cases

  • Anonymous complaints require substantial evidence
  • Conflicts of interest must be fully disclosed
  • Repeat complaints without new evidence won't be reconsidered

Complainant Rights

  • Receive a written response with rationale
  • Request reconsideration with new evidence
  • Escalate to COPE or publisher if dissatisfied

The journal ensures confidentiality and impartiality throughout the process. Typical resolution time is 20 business days (up to 60 for complex cases).

Policy last updated: 11.04.2025.

 

Conflict of Interest Policy

A conflict of interest exists when professional judgment concerning primary interests (research validity) may be potentially influenced by secondary interests (financial gain, personal relationships, academic competition). Competing interests include any financial or non-financial factors that could affect the interpretation or presentation of results.

Author Responsibilities

All authors must:

  • Disclose all potential conflicts of interest upon manuscript submission
  • Declare all research funding sources
  • Report any financial or personal relationships with organizations/individuals that could be interested in the research outcomes
  • Include a conflict of interest statement in a dedicated manuscript section

Reviewer Responsibilities

Reviewers must:

  • Decline to review manuscripts where conflicts exist
  • Disclose any relationships with authors that might affect objectivity
  • Refrain from using unpublished manuscript information for personal benefit

Editorial Responsibilities

The editorial board will:

  • Evaluate declared conflicts of interest
  • Determine necessary disclosure actions
  • Reserve the right to reject submissions with undisclosed significant conflicts
  • Ensure editorial process objectivity

Types of Conflicts

Financial:

  • Research grants and funding
  • Consultancy agreements
  • Stock ownership or patents
  • Paid lectures

Non-financial:

  • Personal relationships
  • Academic competition
  • Intellectual biases
  • Political/religious beliefs

Disclosure Procedure

All participants must complete a disclosure form including:

  • All funding sources
  • Financial and non-financial interests
  • Any other circumstances potentially constituting conflicts

Conflict of Interest Disclosure Form

(For Authors, Reviewers, and Editors of Medical Journals)

Journal: ___________________________________________________
Manuscript Title: __________________________________________
Date of Completion: ________________________________________

Financial Interests

Please check all applicable options:

  • Grants/Funding:
  • Received grants from organizations related to the research topic
  • Specify source: _______________________________
  • Personal Payments:
  • Consulting fees
  • Honoraria for lectures/presentations
  • Expert testimony payments
  • Specify organization: _______________________________
  • Stocks/Patents:
  • Ownership of stocks/options in companies related to the research
  • Patents (pending/issued) for technologies/drugs mentioned in the work
  • Specify details: _______________________________
  • Other Funding:
  • Compensation for study participation
  • Travel/accommodation expenses for conferences
  • Other (specify): _______________________________

Non-Financial Interests

  • Academic/Professional Relationships:
  • Personal/family relationships with authors, reviewers, or editors
  • Competing research projects
  • Membership in advisory boards/associations
  • Intellectual Preferences:
  • Commitment to specific methodologies/theories
  • Public stance on controversial issues related to the topic
  • Other:
  • Political/religious beliefs that may influence data interpretation
  • Other (specify): _______________________________

Declaration

I, _________________________ (Full Name), confirm:

  • No conflicts of interest
  • The presence of conflicts of interest (listed above)

Signature: _________________________
Date: _________________________

Notes:

For pharmaceutically-funded research, additionally specify:

  • Sponsor's role in study design, data collection, and result interpretation.
  • Existence of publication agreements regardless of study outcomes.

The editorial office reserves the right to request supporting documentation.

Non-disclosure may result in manuscript retraction or sanctions per journal policy.

This form complies with ICMJE and COPE guidelines.

Non-Disclosure Consequences

Failure to disclose may result in:

  • Manuscript rejection
  • Article retraction
  • Publication ban
  • Notification to author's institution

Declaration Format

Each publication must contain a "Conflict of Interest" section stating either:

  • The authors declare no conflicts of interest
  • Detailed description of all potential conflicts

Special Cases

Pharmaceutical-funded research requires additional information:

  • Sponsor's role in study design
  • Access to raw data
  • Publication rights

Editorial Board Policy

Editorial members with conflicts must:

  • Recuse themselves from related decision-making
  • Disclose interests prior to discussions
  • Abstain from reviewing affected manuscripts

The journal adheres to ICMJE and COPE guidelines regarding conflicts of interest. This policy undergoes regular review and updates.

This policy applies to all editorial stages – from submission through publication and post-publication discussion. All participants in the publication process are expected to comply fully with these requirements.

Last updated: 11.04.2025.

 

Policy on Data Sharing and Reproducibility

This policy ensures adherence to scientific ethics standards and promotes the advancement of open science. The journal adheres to the principles of open science and strives to ensure transparency, reproducibility, and reliability of published research. This policy outlines the requirements for sharing data, code, and materials necessary for verifying and replicating results.

Data Sharing

Mandatory Data Disclosure
Authors must provide the underlying research data in one of the following formats:

  • Submission to data repositories.
  • Deposition in open databases (if the study involves publicly available datasets).
  • Inclusion in the supplementary materials of the article (if the data volume is small).

Exceptions:

  • Data containing confidential or personally identifiable information may be provided in anonymized form or upon request by the editorial board.
  • In cases of restrictions (e.g., commercial confidentiality, ethical guidelines), authors must justify this in the manuscript.

Data Formats
Data should be submitted in machine-readable formats (CSV, JSON, TXT, XLSX, etc.) with clear documentation (metadata, codebook).

Reproducibility of Results

Provision of Code and Scripts

  • For computational and statistical research, authors must provide source code (R, Python, MATLAB, etc.) in an open repository (GitHub, GitLab, CodeOcean).
  • If proprietary software was used, the version and runtime parameters must be specified.

Methodological Description
Methods should be described in sufficient detail to allow replication of the experiment or analysis.

Reproducibility Verification

  • The editorial board reserves the right to request data and code from authors to verify results.
  • If results cannot be reproduced, the manuscript may be rejected or sent for revision.

Licensing and Data Citation

  • Authors must select an open license (CC BY, CC0) for data and code.
  • If third-party data is used, the source and terms of use must be cited.

Consequences of Non-Compliance

Failure to provide data or code without valid justification may result in:

  • Rejection of the manuscript.
  • Retraction of the publication (if errors or irreproducibility are identified).

Contact Information

For inquiries regarding data sharing, please contact the editorial office: clinvest@mail.ru.

 

Policy on Biomedical Ethical Oversight

This policy governs the ethical aspects of conducting and publishing medical research involving humans, animals, biological materials, and data, ensuring the protection of participants' rights, safety, and confidentiality, and guaranteeing protection of participants' rights, safety, and confidentiality; compliance with international and national regulations; maintenance of trust within the scientific community and society.

The journal adheres to strict principles of biomedical ethics in its publication practices, following international standards, including:

  • WMA Declaration of Helsinki (October 2024);
  • CIOMS Guidelines (Council for International Organizations of Medical Sciences);
  • ICMJE Recommendations (International Committee of Medical Journal Editors);
  • COPE Principles (Committee on Publication Ethics).

When presenting the results of experimental studies involving humans or animals, authors must explicitly state in the relevant section of the manuscript whether the procedures complied with ethical standards.

Ethical Requirements for Human Research

  • All studies involving human participants must be approved by a local or national ethics committee (with approval number provided).
  • For retrospective studies, confirmation of ethical compliance is required.
  • Participants (or their legal representatives) must provide written informed consent (oral consent is permissible only with ethics committee approval if written consent is unattainable).
  • If medical data or biological materials are used, authors must indicate whether consent was obtained for research use.
  • Participant data must be anonymized (identifiable information removed).
  • Compliance with Russia’s Federal Law "On Personal Data" (or equivalent legislation in the study’s country) is mandatory.
  • Research involving children, pregnant women, individuals with mental disorders, or other vulnerable groups requires additional justification for their inclusion and enhanced protective measures.

Ethical Requirements for Animal Research

Experimental studies involving animals must confirm adherence to national and international regulations ensuring humane treatment, including:

  • EAEU Good Laboratory Practice Rules (2016);
  • Russian Ministry of Health Order No. 199n (2016);
  • SanPiN 2.2.1.3218-14 (requirements for animal facilities);
  • GOST 33215-2019 (laboratory animal welfare standards).

Manuscripts must include:

  • The ethics committee approval number for animal research;
  • Measures to minimize suffering (anesthesia, humane euthanasia methods);
  • Justification for animal use (absence of alternative methods).

Authors’ Responsibilities

  • Data integrity: Fabrication, falsification, or image manipulation (e.g., in histology/radiology) is prohibited.
  • Conflict of interest: Authors must disclose financial ties to pharmaceutical companies, equipment manufacturers, or other stakeholders.
  • Plagiarism & duplicate publication: Reusing data (own or others’) without proper citation is forbidden.

Editorial & Reviewer Responsibilities

  • The editorial team verifies ethics committee approval during manuscript review.
  • Reviewers must report suspected ethical violations (e.g., lack of informed consent, animal mistreatment).
  • Editors may request additional documentation (ethics protocols, consent forms) if concerns arise.

Investigation of Violations

If ethical breaches are identified, the journal reserves the right to:

  • Reject the manuscript at any stage;
  • Retract a published article, notifying readers, repositories, and indexing databases;
  • Report to the authors’ institutional ethics committee for further investigation;
  • Impose a submission ban (up to 5 years) on offending authors.

Transparency & Corrections

  • The journal publishes notices, corrections, and retractions if ethical violations are confirmed.
  • Readers and authors may report concerns via email: clinvest@mail.ru.

Effective Date: April 11, 2025.

 

Policy for Post-Publication Discussions and Corrections

The journal is committed to maintaining high standards of scientific publication and ensuring transparency, error correction, and open discussion of published materials. After publication, the following options are available for interaction with authors and readers:

Corrections

  • Minor errors (typos, small inaccuracies in data that do not affect conclusions) – a Corrigendum is published, specifying the changes.
  • Errors introduced by the editorial team/publisher – a Publisher’s Note is issued.
  • Major errors identified by authors or readers that affect the interpretation of results but do not invalidate the main conclusions – an Erratum is published with an explanation of the corrections.

Addenda

  • If authors wish to provide additional significant information clarifying the study (without altering the conclusions), an Addendum may be published.

Comments & Replies

  • Readers may submit a critical comment on an article, which, after peer review, will be published alongside the authors’ response.
  • If the comment reveals serious concerns, the editorial board may initiate a further review of the article.

Article Retraction

An article may be retracted in cases of:

  • Major errors that invalidate the conclusions.
  • Ethical violations (plagiarism, data fabrication, duplicate publication).
  • Unresolved conflicts of interest that were undisclosed at the time of publication.
    A Retraction Notice will be issued, explaining the reasons for retraction.

Updated Versions (Versioning)

  • In exceptional cases (e.g., discovery of new data), an article may be revised and republished as an updated version labeled "Revised Version".

Procedure for Initiating Changes

  • Readers: May submit requests by emailing the editorial office: clinvest@mail.ru.
  • Authors: Must notify the editorial team of any identified errors.
  • Editors: Will make a decision after consulting reviewers and authors.

The journal reserves the right to modify this policy in accordance with COPE (Committee on Publication Ethics) guidelines and international standards of scientific publishing.

Last updated: 11.04.2025.

 

MANUSCRIPT CHECKLIST

Mandatory document for reviewers, editorial board members, technical editors; recommended for manuscript authors.

1. General Provisions

1.1. The purpose of this methodology is to ensure an objective, standardized, and ethically sound evaluation of manuscripts aimed at advancing the patient‑centered model in medicine and pharmacy, using a specialized Manuscript Checklist.

1.2. The methodology is based on:

  • International guidelines from the EQUATOR Network (CONSORT, STROBE, PRISMA, STARD, TRIPOD, CHEERS, STROPS, CARE, SRQR, CROSS, etc.);

  • Principles of patient‑centeredness (accounting for patient values, preferences, and resources, shared decision‑making);

  • Reporting standards for real‑world data/real‑world evidence (RWD/RWE) studies;

  • Requirements of the Russian Federation legislation, including Federal Law No. 86‑FZ “On Genomic Registration”, Federal Law No. 323‑FZ “On the Fundamentals of Protecting the Health of Citizens” (ethics committees, informed consent);

  • The internal policy of the journal (manuscript structure, Vancouver style, mandatory declarations).

1.3. The reviewer is obliged to use the current version of the checklist (Appendix). A review submitted without a completed checklist will not be accepted by the editorial office.

2. Key aspects of manuscript evaluation in this journal

When reviewing, special attention should be paid to the following aspects depending on the article type:

AspectWhat to verify
Patient centerednessAre the patient’s goals, preferences, values and economic possibilities taken into account? Is shared decision‑making described? Are quality‑of‑life assessment tools provided?
Personalization / precisionAre “omics” biomarkers (genomic, epigenomic, metabolomic) used to select therapy? Is the choice of biomarkers justified?
Real‑world data / real‑world evidence (RWD/RWE)If RWD are used, are the data source (registries, EHRs, surveys), processing methods, bias control, and compliance with standards (RECORD, GRACE) described?
Cell and gene therapyAre details of the product (vector, dose, route of administration), response criteria, long‑term safety, and ethical aspects (including Ministry of Health of the Russian Federation) provided?
Pharmacoeconomics and health technology assessmentDoes the manuscript follow the CHEERS 2022 standard? Are patient and system costs accounted for, cost‑effectiveness analysis, willingness‑to‑pay threshold?
Digital technologies (mobile health, AI)Are validation of digital tools, personal data protection, and decision‑support algorithms described?
Drug safetyAre pharmacovigilance data, adverse reaction analysis, counseling for responsible self‑medication presented?

3. Scoring scale (unified for all criteria)

ScoreInterpretationTypical examples
0Unsatisfactory / absent / critical deficiencyNo ethics approval; informed consent not described; no analysis of patient preferences; transfer of genetic data abroad without permission (FL‑86)
1Satisfactory / partially meets / requires revisionPatient preferences mentioned but not operationalized; RWE study without bias control; incomplete description of genotyping method
2Excellent / fully meetsComplete description of shared decision‑making, validated patient‑reported outcomes (PROs), adherence to reporting standards, ethics and legislation

If a criterion is not applicable to the manuscript type (e.g., a flow diagram for a case report), the reviewer assigns 1 or 2 with the comment “Not applicable”. The total score is not reduced.

4. Reviewer workflow

4.1. Preliminary check (by the handling editor)

Ensure the presence of mandatory elements:

  • Ethics committee approval (protocol number) or justification for its absence;

  • Informed consent (including “broad” consent for biobanks / genetic data);

  • For studies with genetic data – a declaration that raw genetic data will not be transferred outside the Russian Federation (FL‑86);

  • Structured abstract;

  • Declaration of conflict of interest and funding.

If any of these elements is missing, the manuscript is rejected without peer review (option “d”).

4.2. Main stage (reviewer)

  1. Receive the manuscript and the checklist form.

  2. Fill in the header: article title, type of publication (choose from the journal’s sections or specify: “Original research”, “Review”, “Case report”, “RWD study”, “Pharmacoeconomics”, “Expert opinion”, etc.).

  3. Evaluate each criterion sequentially (total 24 criteria, maximum score – 48 points).

  4. For scores of 0 or 1, mandatory detailed comment with page/line number.

  5. Verify compliance with the chosen reporting standard (e.g., for RWD – RECORD/GRACE, for pharmacoeconomics – CHEERS).

  6. Calculate the total score.

4.3. Prohibitions and restrictions

  • Use of artificial intelligence (ChatGPT and similar) to generate the review or analyze the manuscript is prohibited (breach of confidentiality).

  • The reviewer must declare any potential conflict of interest.

  • Discussion of the manuscript with third parties is not allowed.

5. Final conclusion and recommendations to the editorial office

CodeRecommendationConditions
aACCEPT AS ISFull compliance with the chosen standard (CONSORT, STROBE, PRISMA, CHEERS, STROPS, CARE, RECORD, etc.), all criteria ≥1, most = 2; ethics and patient centeredness are observed; high practical relevance for the Russian Federation.
bACCEPT AFTER REVISIONThe work is of interest but has correctable shortcomings (e.g., incomplete description of patient preferences, lack of quality‑of‑life analysis, incomplete bibliography).
cREQUIRES ADDITIONAL REVIEWComplex analysis (e.g., pharmacoeconomic modeling, NGS/bioinformatics, advanced RWD statistics) requires evaluation by a specialised expert.
dREJECTUncorrectable flaws: absence of ethics approval, mismatch between design and objectives, transfer of genetic data abroad without permission, gross methodological violations, plagiarism.

APPENDIX: MANUSCRIPT CHECKLIST (mandatory)

CHECKLIST for evaluating a manuscript submitted to the journal “Patient‑Centered Medicine and Pharmacy”

ARTICLE TITLE:

Type of manuscript (underline or specify):
Original research / Literature review / Systematic review / Meta‑analysis / Case report / Case series / RWD study (real‑world data) / Pharmacoeconomic study / Health technology assessment / Expert opinion / Practical recommendations / Methodological article / Other: __________________________

 
CriterionScore (0‑2)Comment (for 0 or 1 – mandatory, with page/line reference)
Section 1. Patient centeredness and relevance  
Title reflects the essence of the patient‑centered approach (if applicable)  
Relevance is justified from the perspective of patient needs, preferences or values (including description of gaps in personalization)  
Abstract is structured (IMRAD or adapted for RWD/CHEERS/CARE), contains key results and quality‑of‑life / PRO measures if applicable  
Section 2. Compliance with methodology and reporting standards  
Introduction: hypothesis / objective clearly stated; patient heterogeneity of response is considered  
Methods: design described (prospective, retrospective, RWD cohort, registry, etc.), inclusion/exclusion criteria, data source (for RWD – database, period, validation procedures)  
Methods: for personalized therapy – biomarkers specified (genomic, proteomic, etc.), laboratory analysis method, quality control, population stratification  
Methods: for genetic / “omics” data – Hardy‑Weinberg equilibrium tested (for population studies), correction for multiple comparisons, power calculation  
Methods: for interventions (including cell/gene therapy) – product details, dose, route of administration, response and safety criteria  
Methods: statistical analysis fully described (covariate adjustment, handling of missing data, sensitivity analysis)  
Methods: for pharmacoeconomics / HTA – perspective (healthcare system, society, patient), time horizon, discount rate, uncertainty analysis  
Results: participant characteristics presented (including demographic, clinical and genetic data) considering factors relevant to personalization  
Results: primary and secondary outcomes (incl. PROs, quality of life, patient satisfaction) presented with effect estimates (CI, p‑values)  
Results: for RWD – measures to minimise bias (selection, calibration, pseudo‑randomisation, IPTW, E‑value) described  
Flow diagram (patient flow, registry record selection) presented if applicable  
Section 3. Patient involvement and shared decision‑making  
Described how patient preferences, values or economic constraints were taken into account when choosing therapy (e.g., questionnaires, discrete choice, consultation)  
For studies involving an intervention, it is stated whether patients received information on risks and alternatives, and how their consent was documented  
Section 4. Ethical, legal and financial aspects  
Ethics committee (IRB) protocol number, approval date; description of informed consent procedure (including “broad” consent for biobanks or genetic data)  
For studies with genetic data – declaration that raw data will not be transferred outside the Russian Federation or permission according to FL‑86  
Declaration of conflict of interest and funding sources (including grants, manufacturer support)  
For pharmacoeconomic studies – statement of no undisclosed sponsorship or description of sponsor’s role in the analysis  
Section 5. Discussion, limitations and conclusions  
Discussion begins with the main result; own data compared with literature (including Russian cohorts)  
Limitations discussed: applicability to different patient groups, potential biases, heterogeneity of effect, economic generalizability  
Conclusions correspond to the objectives, contain practical recommendations for patient‑centered practice and/or the healthcare system of the Russian Federation  
Section 6. Formatting and quality of writing  
Reference list formatted according to Vancouver style (including Russian sources with (In Russ.) and DOI). The article is written in scientific language, with good grammar and clarity  
TOTAL SCORE (max. 48)/48 

CONCLUSION AND RECOMMENDATIONS TO THE EDITORIAL OFFICE
(Select one option, provide a brief justification, with emphasis on patient centeredness and compliance with the reporting standard)

a) ☐ ACCEPT AS IS
Justification: 

_________________________________________________________________

b) ☐ ACCEPT AFTER REVISION
Justification (key comments): 

_________________________________________________________________

c) ☐ REQUIRES ADDITIONAL REVIEW (Specialist: _____________________________)
Justification: 

_________________________________________________________________

d) ☐ REJECT
Justification (uncorrectable flaws): 

_________________________________________________________________

Date: “__” ______________ 20__
Reviewer’s full name: ______________________________________________

6. Final provisions

6.1. This methodology and checklist come into force upon approval by the Editor‑in‑Chief of the journal “Patient‑Centered Medicine and Pharmacy”.

6.2. All reviewers are required to confirm that they have read the document before starting work.

6.3. The editorial board reserves the right to amend the methodology with a 30‑day notice to reviewers.

Developed based on: EQUATOR Network, patient‑centeredness principles (Patient School, shared decision‑making), CONSORT, STROBE, PRISMA, RECORD, GRACE, CHEERS, STROPS, CARE standards, and the journal’s own requirements.

Version: 3 dated 08.05.2026.

 

Policy upon detection of fraudulent publication

On Responsibility for Falsified Research (including falsification committed using Generative Artificial Intelligence)

  1. General Provisions and Definitions

1.1. A falsified publication is defined as a manuscript in which:

  • genuine primary data from experiments, observations, surveys, or measurements are absent;
  • numerical values, graphs, statistical relationships, or conclusions are artificially generated, including by means of Generative Artificial Intelligence (AI) (e.g., ChatGPT, GigaChat, YandexGPT, Midjourney, DALL-E, DeepSeek, and similar);
  • fictitious sources are cited, or the content of real sources is distorted;
  • a methodology is described but was not actually applied.

1.2. The use of AI as a supporting tool (editing, structuring, translation, grammar and spelling checking, hypothesis generation) shall not be considered falsification, provided that such use is explicitly disclosed in a special disclaimer — the Declaration on the Use of AI (for example: "In preparing this work, the author(s) used [NAME AND VERSION OF THE TOOL] for [RATIONALE]. After using this tool/service, the author(s) reviewed and edited the content and accept(s) full responsibility for the content of the publication").
Data analysis, code generation for processing real data, research design, literature searches in the Materials and Methods section, and the creation of illustrations, schemes, or diagrams shall be disclosed in the figure caption.

1.3. Exclusive responsibility for the accuracy and authenticity of all data lies with the author(s).

  1. Civil Liability (Civil Code of the Russian Federation)

Upon confirmation of falsification, the following measures based on the norms of the Civil Code of the Russian Federation shall apply to the author(s):

2.1. Protection of the Journal's Business Reputation (Article 152 of the Civil Code)
The Journal shall have the right to seek through court:

  • a retraction of the false information (the falsified research) in the same manner in which it was disseminated;
  • removal of the published article from the website and from databases;
  • compensation for moral harm caused by the dissemination of information defaming the Journal's business reputation (the amount shall be determined by the court, but the Journal shall claim no less than 500,000 rubles).

Legal basis:
Article 152, paragraph 11 of the Civil Code: "The rules on the protection of a citizen's business reputation shall apply accordingly to the protection of the business reputation of a legal entity."

2.2. Recovery of Damages (Articles 15, 393 of the Civil Code)
The Journal shall have the right to recover from the authors in full:

  • costs of peer review (actual cost — up to 30,000 rubles);
  • costs of editing, typesetting, proofreading, DOI assignment (up to 50,000 rubles);
  • costs of publication in the printed version (up to 20,000 rubles);
  • lost profits (e.g., refusal of a publisher to continue cooperation with the Journal due to reputational damage).

Legal basis:
*Article 15 of the Civil Code: "A person whose right has been violated may demand full compensation for the losses caused to him/her."*

2.3. Invalidity of the Transaction (Articles 168, 179 of the Civil Code)
The submission of a manuscript and the conclusion of an author agreement with full falsification of data shall be deemed an invalid transaction concluded under the influence of fraud.

Consequences: bilateral restitution shall not apply; everything received by the Journal (editorial and publication fees) shall remain with the Journal, and what the author received (publication) shall be annulled.

Legal basis:
Article 179, paragraph 2 of the Civil Code: "A transaction concluded under the influence of fraud may be declared invalid by a court at the claim of the injured party. Fraud also includes intentional silence about circumstances which the person should have disclosed."

2.4. Unjust Enrichment (Article 1102 of the Civil Code)
If the author received an honorarium or other payments from the Journal for a falsified article, he/she shall be obliged to return them as unjust enrichment within 10 days of the date the claim is made.

Legal basis:
Article 1102 of the Civil Code: "A person who, without grounds established by law or by transaction, has acquired property at the expense of another person, shall be obliged to return to the latter the unjustly acquired property."

  1. Administrative Liability (Code of Administrative Offences of the Russian Federation)

The Journal shall have the right (and, where signs exist, the obligation) to submit materials to Roskomnadzor, the Ministry of Internal Affairs, or the Prosecutor's Office to hold the author administratively liable under the following articles:

3.1. Dissemination of False Information (Article 13.15 of the Administrative Code)
This shall apply if the falsified research concerns socially significant topics (medicine, safety, ecology) and misleads an indefinite circle of persons.
Sanction: a fine on citizens from 30,000 to 100,000 rubles; on officials — from 60,000 to 200,000 rubles; on legal entities — from 200,000 to 500,000 rubles.

3.2. Violation of the Procedure for Using AI Technologies
As of the date of this document, no special offence is provided for. However, the Journal declares that the generation of false data using AI shall be considered an aggravating circumstance under Article 4.3 of the Administrative Code (commission of an offence using technical means).

  1. Criminal Liability (Criminal Code of the Russian Federation)

The Journal hereby notifies that a falsified research may contain elements of crimes provided for by the following articles of the Criminal Code. If any of the signs listed below are present, the Journal shall be obliged to file a report with the Investigative Committee or the Ministry of Internal Affairs.

4.1. Fraud (Article 159 of the Criminal Code)

Conditions for application:

  • The falsified research was presented to obtain a grant, subsidy, state contract, budget funding, scholarship, or prize.
  • Funds or other property (including the right to publication at the expense of a grant) were transferred to the author.

Qualifying features:

  • On a large scale (over 250,000 rubles) — Part 2 of Article 159 of the Criminal Code → a fine of up to 300,000 rubles, or compulsory labour for up to 3 years, or imprisonment for up to 3 years.
  • On an especially large scale (over 1 million rubles) — Part 4 of Article 159 of the Criminal Code → imprisonment for up to 10 years with a fine of up to 1 million rubles.
  • Committed by a group of persons pursuant to a prior conspiracy (e.g., by all co-authors) — Part 2 of Article 159 of the Criminal Code.

Legal basis:
Article 159, paragraph 1 of the Criminal Code: "Theft of another's property or acquisition of the right to another's property by fraud or abuse of trust."

4.2. Official Forgery (Article 292 of the Criminal Code)
Applies if the author is an official (employee of a state university, research institute, state body, expert of the Ministry of Education and Science) and has knowingly included false information in an official report, expert opinion, or dissertation council.
Sanction: a fine of up to 80,000 rubles, or compulsory labour for up to 480 hours, or corrective labour for up to 2 years, or arrest for up to 6 months.

4.3. Falsification of Evidence (Article 303 of the Criminal Code)
Applies if the falsified research is presented to a court as an expert opinion or scientific justification in a civil, arbitration, or criminal case.
Sanction (Part 1 of Article 303 of the Criminal Code): a fine of up to 300,000 rubles, or compulsory labour for up to 480 hours, or arrest for up to 4 months.

4.4. Copyright Infringement (Article 146 of the Criminal Code)
Applies if in the process of falsification the author has unlawfully used another person's real data (e.g., copied graphs from another article) or appropriated authorship.
Sanction (Part 2 of Article 146 of the Criminal Code): a fine of up to 200,000 rubles, or compulsory labour for up to 480 hours, or arrest for up to 6 months.

4.5. Negligence (Article 293 of the Criminal Code) — for a research supervisor or reviewer
Applies if they knew for certain about the falsification but allowed publication, and this caused major damage (to the reputation of the Journal or the state budget).
Sanction: a fine of up to 200,000 rubles, or corrective labour for up to 2 years, or imprisonment for up to 3 months (Part 1 of Article 293 of the Criminal Code).

  1. Special Legal Consequences

5.1. Annulment of an Academic Degree (Article 4 of Federal Law No. 127-FZ "On Science and State Scientific and Technical Policy")
The Journal shall submit a representation to the Higher Attestation Commission (VAK) under the Ministry of Education and Science of the Russian Federation for the annulment of a Candidate's or Doctor's degree diploma if the falsified research formed the basis of a dissertation.

5.2. Expulsion from an Educational Institution (Article 43 of Federal Law No. 273-FZ "On Education in the Russian Federation")
For submitting a falsified research as a term paper, graduate thesis, or Master's thesis — expulsion without the right to reinstatement for "academic dishonesty."

  1. Joint and Several Liability of Co-authors

6.1. All co-authors shall bear joint and several civil liability (Article 322 of the Civil Code) for losses incurred by the Journal in connection with falsification.
6.2. Each co-author, by signing the author agreement, confirms that he/she has personally reviewed the raw data and methodology. A reference to the fact that "the first author was responsible for the data" or "the data was generated by AI" shall not be accepted and shall not serve as a ground for exemption from liability (Article 322 of the Civil Code).

  1. Procedure for Applying Sanctions

7.1. Upon detection of signs of falsification, the Editorial Board shall establish an Ethics Committee (3 members of the Editorial Board not affiliated with the authors).
7.2. A request for raw data shall be sent to the author(s). The deadline shall be 14 calendar days. Refusal, inability to provide raw data, or provision of data manifestly generated by AI (according to the conclusion of systems such as Antiplagiat, Domate, Rukontest, Plagiat AI, or similar) shall be deemed confirmation of falsification.
7.3. The decision on retraction shall be published in the nearest issue of the Journal with the wording: "The article has been retracted due to complete falsification of data, including the use of Generative AI."
7.4. Within 30 days from the date the fact is established, the Journal shall send the materials:

  • to law enforcement authorities (where signs of Articles 159, 292, 303 of the Criminal Code are present);
  • to the VAK / Ministry of Education and Science (where an academic degree is held);
  • to the Retraction Watch system and databases (Scopus, WoS, RSCI/РИНЦ).
  1. Absence of Mitigating Circumstances

The following arguments shall not constitute grounds for mitigating or setting aside liability:

  • "The data was generated by a neural network without my knowledge";
  • "I do not know how to verify the quality of AI-generated data";
  • "AI is a new tool, and the law does not regulate it";
  • "Other authors do the same."

The Journal follows the position of the Higher Attestation Commission (VAK) and the Ministry of Education and Science: concealment of the use of AI to generate false data is a form of fraud, equivalent to direct forgery.

  1. Final Provisions

9.1. This Policy is an integral part of the Author Agreement (paragraph 2 of Article 428 of the Civil Code) and shall be published on the Journal's website in open access.
9.2. By submitting a manuscript, the author confirms that he/she has read the Policy and agrees to its terms in full.
9.3. The Policy shall apply to manuscripts submitted after the date of its publication, as well as to already published articles if falsification is discovered at any time after publication (the statute of limitations shall not apply due to the continuing nature of the violation, Article 208 of the Civil Code).

Appendix:
Signature of each co-author confirming their awareness of the Policy and responsibility for falsification.

"I, [FULL NAME], confirm that I have read the Journal's Policy on Responsibility for Falsified Research. I am aware that complete falsification, including the use of Generative AI, entails civil liability (Articles 15, 152, 179, 1102 of the Civil Code) and potential criminal liability (Articles 159, 292, 303, 146 of the Criminal Code). I undertake to keep the primary data for at least 5 years and to provide them at the first request of the Editorial Board. I am aware that a reference to lack of knowledge of the origin of the data does not relieve me of liability."

Effective Date: 10 May 2026
Status: Integral part of the Author Agreement and of the Journal's Publication Ethics.



115522, Moscow, st. Moskvorechye, 4, building 5, apt. 129, OKI Publishing House LLC

Processing of personal data
supported by NEICON (Elpub lab)